<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6731254/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Overview of published articles reporting on genetics and deep brain stimulation in Parkinson’s disease</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Reference</th>
   <th colspan="1" rowspan="1" id="0-1-.">Study design</th>
   <th colspan="1" rowspan="1" id="0-2-.">Material</th>
   <th colspan="1" rowspan="1" id="0-3-.">Follow-up</th>
   <th colspan="1" rowspan="1" id="0-4-.">Main finding</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Pal et al. 
    <sup>
     <a ref-type="bibr" rid="CR21">21</a>
    </sup>
   </td>
   <td>Genetic screening of DBS vs non-DBS EOPD cohorts with assessment of predictors for DBS treatment</td>
   <td>98 DBS-treated EOPD vs 654 non-DBS (US)</td>
   <td>Cross-sectional</td>
   <td>PD with either 
    <i>GBA</i> (12,1% vs 8,0%), 
    <i>LRRK2</i> (5,1% vs 3,9%) or parkin (10,2% vs 6,1%) mutations were significantly more common in DBS group compared with the non-DBS group (26,5% vs 16,8%). 
   </td>
  </tr>
  <tr>
   <td rowspan="2">Angeli et al. 
    <sup>
     <a ref-type="bibr" rid="CR20">20</a>
    </sup>
   </td>
   <td rowspan="2">Genetic screening of DBS cohort with assessment of DBS outcomes in MC vs iPD</td>
   <td rowspan="2">94 DBS-treated PD (UK)</td>
   <td>Cross-sectional</td>
   <td>PD with either 
    <i>GBA</i> (17,0%), 
    <i>LRRK2</i> (5,3%) or parkin (8,5%) mutations were significantly more common in DBS group (29%) compared to population-representative cohorts of PD. 
   </td>
  </tr>
  <tr>
   <td>1 year (+5years)</td>
   <td>No significant difference in improvement of UPDRS III score between mutation carrier groups and non-carriers postoperatively. 
    <i>GBA</i> mutation carriers had a larger cognitive decline compared to non-carriers at five year follow-up. 
   </td>
  </tr>
  <tr>
   <td rowspan="2">Johansen et al. 
    <sup>
     <a ref-type="bibr" rid="CR19">19</a>
    </sup>
   </td>
   <td rowspan="2">Genetic screening of DBS vs non-DBS cohorts with assessment of DBS outcomes in MC vs iPD</td>
   <td rowspan="2">60 DBS-treated PD vs 570 non-DBS (Norway)</td>
   <td>Cross-sectional</td>
   <td>PD with either 
    <i>LRRK2</i> (5% vs 0,9%) or parkin (16,7% vs 3,1%) mutations were more common in the DBS group compared with the non-DBS group. No difference in the proportion of 
    <i>PINK1</i>-carriers in the two groups. 
   </td>
  </tr>
  <tr>
   <td>1, 3, and 5 years</td>
   <td>No significant differences in DBS outcome between mutation carriers, regardless of mutation type, and non-carriers looking at clinical features at baseline compared to follow-up.</td>
  </tr>
  <tr>
   <td>Greenbaum et al. 
    <sup>
     <a ref-type="bibr" rid="CR28">28</a>
    </sup>
   </td>
   <td>Statistical comparison of DBS outcomes in MC vs iPD</td>
   <td>13 
    <i>LRRK2</i> G2019S PD vs control group of 26 iPD (Israel) 
   </td>
   <td>6–12 months + 3 years</td>
   <td>Significant improvement of UPDRS-III score and LEDD in both groups, but no significant difference between MC and iPD at baseline or at follow-up.</td>
  </tr>
  <tr>
   <td>Schupbach et al. 
    <sup>
     <a ref-type="bibr" rid="CR29">29</a>
    </sup>
   </td>
   <td>Statistical comparison of DBS outcomes in MC vs iPD</td>
   <td>8 
    <i>LRRK2</i> G2019S PD and 1 
    <i>LRRK2</i> T2032S PD vs 60 iPD (France) 
   </td>
   <td>6–12 months</td>
   <td>No significant difference in improvement of UPDRS II-IV or LEDD reduction between the two groups.</td>
  </tr>
  <tr>
   <td>Sayad et al. 
    <sup>
     <a ref-type="bibr" rid="CR30">30</a>
    </sup>
   </td>
   <td>Descriptive comparison of DBS outcomes in MC vs iPD</td>
   <td>15 
    <i>LRRK2</i> G2019S PD vs control group of 12 iPD (Algerie) 
   </td>
   <td>2 years</td>
   <td>More pronounced postoperative improvement of UPDRS III off-medication (51.1% vs 25.5%), S&amp;E and H&amp;Y with DBS in 
    <i>LRRK2</i>-group. 
   </td>
  </tr>
  <tr>
   <td>Gomez-Esteban et al. 
    <sup>
     <a ref-type="bibr" rid="CR31">31</a>
    </sup>
   </td>
   <td>Descriptive comparison of DBS outcomes in MC vs iPD</td>
   <td>4 
    <i>LRRK2</i> R1441G PD vs 41 iPD (Basque country, Spain) 
   </td>
   <td>6 months</td>
   <td>Less improvement of UPDRS II-III scores and quality of life in MC compared to iPD.</td>
  </tr>
  <tr>
   <td>Lesage et al. 
    <sup>
     <a ref-type="bibr" rid="CR32">32</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>
    <p>2 
     <i>LRRK2</i> G2019S PD (France) 
    </p>
    <p>1 
     <i>LRRK2</i> T2031S PD (Spain) 
    </p>
   </td>
   <td>7 years</td>
   <td>Sustained long-term improvement in UPDRS III.</td>
  </tr>
  <tr>
   <td>Breit et al. 
    <sup>
     <a ref-type="bibr" rid="CR33">33</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>LRRK2</i> R793M PD (Germany) 
   </td>
   <td>1 + 8 years</td>
   <td>Sustained long-term improvement in UPDRS III and reduction in LEDD.</td>
  </tr>
  <tr>
   <td>Perju-dumbrava et al. 
    <sup>
     <a ref-type="bibr" rid="CR34">34</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>LRRK2</i> Y1699C PD (Australia) 
   </td>
   <td>2/6 weeks + 2,5 years</td>
   <td>Sustained improvement in UPDRS-III and sustained reduction &gt;50% in LEDD, but a mild increase in dyskinesia.</td>
  </tr>
  <tr>
   <td>Stefani et al. 
    <sup>
     <a ref-type="bibr" rid="CR35">35</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>LRRK2</i> G2019S PD (Italy) 
   </td>
   <td>1 + 3 months</td>
   <td>Improvement of UPDRS-II and UPDRS-III with DBS, but sensitive to levodopa-induced dyskinesia.</td>
  </tr>
  <tr>
   <td>Healy et al. 
    <sup>
     <a ref-type="bibr" rid="CR26">26</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>12 
    <i>LRRK2</i> G2019S-PD (UK) 
   </td>
   <td>Unspecified</td>
   <td>Eight patient had a good or excellent outcome, two moderate and two poor.</td>
  </tr>
  <tr>
   <td>Puschmann et al. 
    <sup>
     <a ref-type="bibr" rid="CR36">36</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>LRRK2</i> N1437H PD (Sweden) 
   </td>
   <td>Few weeks + 6 months</td>
   <td>Poor outcome postoperatively, committed suicide after six months.</td>
  </tr>
  <tr>
   <td>Lohmann et al. 
    <sup>
     <a ref-type="bibr" rid="CR38">38</a>
    </sup>
   </td>
   <td>Statistical comparison of DBS outcomes in MC vs iPD</td>
   <td>14 parkin-PD (1 homozygous, 6 compound heterozygous, 7 single heterozygous) vs 39 iPD (France)</td>
   <td>12–24 months</td>
   <td>
    <p>Significantly earlier age at onset and longer disease duration in patients with two parkin mutations.</p>
    <p>Postoperatively no differences in UPDRS III improvement, significantly lower LEDD, lower MATTIS dementia rating scale score and higher Hoehn and Yahr score (non-significant if excluding one case of ballistic dyskinesia) in double mutation carriers.</p>
   </td>
  </tr>
  <tr>
   <td rowspan="2">Kim et al. 
    <sup>
     <a ref-type="bibr" rid="CR39">39</a>
    </sup>
   </td>
   <td rowspan="2">Statistical comparison of DBS outcomes in MC vs iPD</td>
   <td rowspan="2">3 homozygous/compound heterozygous parkin-PD vs 9 iPD (South Korea)</td>
   <td>2 years</td>
   <td>Significantly younger AAO and significantly longer disease duration before surgery in MC than NC.</td>
  </tr>
  <tr>
   <td>5 years</td>
   <td>No significant difference in improvement of UPDRS-II-, UPDRS-III-score or H&amp;Y between the two groups.</td>
  </tr>
  <tr>
   <td>Romito et al. 
    <sup>
     <a ref-type="bibr" rid="CR40">40</a>
    </sup>
   </td>
   <td>Statistical comparison of DBS outcomes in MC vs iPD</td>
   <td>
    <p>5 Parkin-PD (1 compound heterozygous, 4 single heterozygous)</p>
    <p>31 iPD (Italy)</p>
   </td>
   <td>21.6 ± 13.1 months</td>
   <td>No difference in mean UPDRS III improvement on stim-off-med (56% vs 51%). LEDD reduced by a higher degree in the parkin group, but not statistically significant (76% vs 55%).</td>
  </tr>
  <tr>
   <td>Moro et al. 
    <sup>
     <a ref-type="bibr" rid="CR41">41</a>
    </sup>
   </td>
   <td>Descriptive comparison of DBS outcomes in MC vs iPD</td>
   <td>11 parkin-PD (4 homozygous, 2 compound heterozygous, 5 single heterozygous) + 1 homozygous PINK1-PD vs 68 iPD (Canada/Germany)</td>
   <td>
    <p>Short-term: 3–12 months</p>
    <p>Long term: 3–6 years</p>
   </td>
   <td>In short-term follow-up less UPDRS improvement (36% versus 56%) and higher burden of axial symptoms in MC. No difference in long-term follow-up (UPDRS III improvement on stim-off-med vs off-med preoperatively 42% vs 44%,).</td>
  </tr>
  <tr>
   <td>Capecci et al. 
    <sup>
     <a ref-type="bibr" rid="CR42">42</a>
    </sup>
   </td>
   <td>Descriptive aase report</td>
   <td>1 homozygous parkin-PD (Italy)</td>
   <td>12 months</td>
   <td>UPDRS III score improved by 84%, LEDD reduced by 66%, severe dyskinesias disappeared. Improvement in both PDQ-39, BDI and BDS measures.</td>
  </tr>
  <tr>
   <td>Isaacs et al. 
    <sup>
     <a ref-type="bibr" rid="CR14">14</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 compound heterozygous Parkin-PD (USA)</td>
   <td>Several years</td>
   <td>
    <p>1st DBS (STN): several years of significant motoric benefit, but stimulation- and medication-refractory dystonia.</p>
    <p>2nd DBS (GPi, due to dystonia): dystonic symptoms only mildly improved.</p>
   </td>
  </tr>
  <tr>
   <td>Moll et al. 
    <sup>
     <a ref-type="bibr" rid="CR43">43</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 compound heterozygous Parkin-PD (Germany)</td>
   <td>Unspecified</td>
   <td>Improvement of motor symptoms and daytime drowsiness, LEDD reduced.</td>
  </tr>
  <tr>
   <td>Nakahara et al. 
    <sup>
     <a ref-type="bibr" rid="CR44">44</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 homozygous parkin-PD with a co-existing heterozygous 
    <i>PINK1</i>-mutation (Japan) 
   </td>
   <td>12 days + 8 months</td>
   <td>DBS afer 45 years’ disease duration. Improvement of UPDRS I-IV-scores and LEDD-reduction by &gt;50%.</td>
  </tr>
  <tr>
   <td>Lefaucheur et al. 
    <sup>
     <a ref-type="bibr" rid="CR45">45</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 compound heterozygous parkin-PD (France)</td>
   <td>6 months</td>
   <td>DBS after 44 years’ disease duration. Improvement of UPDRS III and IV by &gt;50%, LEDD reduction by 67% postoperatively and stable cognitive function.</td>
  </tr>
  <tr>
   <td>Thompson et al. 
    <sup>
     <a ref-type="bibr" rid="CR13">13</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>2 homozygous parkin-PD (USA)</td>
   <td>3 + 8 years</td>
   <td>
    <p>GPi-DBS: long-term benefit &gt;8 years (less improvement than patient treated with STN-DBS).</p>
    <p>STN-DBS: sustained improvement &gt;3 years.</p>
   </td>
  </tr>
  <tr>
   <td>Hassin-Baer et al. 
    <sup>
     <a ref-type="bibr" rid="CR46">46</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>3 homozygous parkin-PD (Israel)</td>
   <td>Unspecified</td>
   <td>Modest improvement in appendicular symptoms, no change in axial features (particularly PIGD and LBP).</td>
  </tr>
  <tr>
   <td>Antonini et al. 
    <sup>
     <a ref-type="bibr" rid="CR50">50</a>
    </sup> 2011 
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>SNCA</i>-duplication PD (Italy) 
   </td>
   <td>12 months</td>
   <td>UPDRS-III score reduced by 64%, LEDD reduced by 50% and depression severity decreased on BDI. Complicated by right foot dystonia and nocturnal akinesia. Postoperative decline in verbal fluency and attention shifting.</td>
  </tr>
  <tr>
   <td>Elia et al. 
    <sup>
     <a ref-type="bibr" rid="CR51">51</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>SNCA</i>-duplication PD (Italy) 
   </td>
   <td>3 years</td>
   <td>UPDRS score improved by 42% and LEDD reduced by 58%. MMSE worsened from 26,3/30 to 23,2/30.</td>
  </tr>
  <tr>
   <td>Perandones et al. 
    <sup>
     <a ref-type="bibr" rid="CR15">15</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>SNCA</i>-duplication PD (Argentina) 
   </td>
   <td>1 month</td>
   <td>Improvement in motor features and reduction in pharmacological treatment.</td>
  </tr>
  <tr>
   <td>Sheerin et al. 
    <sup>
     <a ref-type="bibr" rid="CR54">54</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>VPS35</i> D620N-PD (UK) 
   </td>
   <td>Unspecified</td>
   <td>Good outcome.</td>
  </tr>
  <tr>
   <td>Kumar et al. 
    <sup>
     <a ref-type="bibr" rid="CR55">55</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>VPS35</i> D620N-PD (Germany) 
   </td>
   <td>Unspecified</td>
   <td>Modest effect, complicated by dysarthria.</td>
  </tr>
  <tr>
   <td>Sundal et al. 
    <sup>
     <a ref-type="bibr" rid="CR56">56</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>VPS35</i> D620N-PD (USA) 
   </td>
   <td>Unspecified</td>
   <td>Good outcome.</td>
  </tr>
  <tr>
   <td>Fleury et al. 
    <sup>
     <a ref-type="bibr" rid="CR57">57</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>2 
    <i>VPS35</i> D620N-PD (Swiss) 
   </td>
   <td>1 and 8 year(s)</td>
   <td>First patient with 76% improvement of UPDRS III (on/off versus off/off) both 1 and 8 years postoperatively. Second patient with 36% improvement of UPDRS 1 year postoperatively, but increased frequency of freezing episodes and falls.</td>
  </tr>
  <tr>
   <td>Chen et al. 
    <sup>
     <a ref-type="bibr" rid="CR58">58</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>VPS35</i> D620N-PD (Taiwan) 
   </td>
   <td>5 years</td>
   <td>37% improvement UPDRS III-score (off-medication), and decrease of peak-dose dyskinesia.</td>
  </tr>
  <tr>
   <td>Borrelini et al. 
    <sup>
     <a ref-type="bibr" rid="CR16">16</a>
    </sup>
   </td>
   <td>Descriptive case report</td>
   <td>1 
    <i>PINK1</i> L347P-PD (Philippines) 
   </td>
   <td>1 + 2 months</td>
   <td>No difference in UPDRS III-score on-medication, but reduction in UPDRS IV-score and LEDD postoperatively.</td>
  </tr>
  <tr>
   <td>Lythe et al. 
    <sup>
     <a ref-type="bibr" rid="CR17">17</a>
    </sup>
   </td>
   <td>Statistical comparison of DBS outcomes in MC vs NC</td>
   <td>17 
    <i>GBA</i>-PD vs 17 non-GBA PD (UK) 
   </td>
   <td>Mean 7.5 years</td>
   <td>Significantly worse cognitive outcome (measured by AMSS) and quality of life assessment (PDQ-39) and significantly greater burden of non-motor symptoms (NMSS) for MC compared to NC. No significant difference in UPDRS-III-scores and LEDD-reduction between the two groups.</td>
  </tr>
  <tr>
   <td>Weiss et al. 
    <sup>
     <a ref-type="bibr" rid="CR66">66</a>
    </sup>
   </td>
   <td>Descriptive comparison of DBS outcomes in MC vs NC</td>
   <td>1 N370S 
    <i>GBA</i>-PD + 2 L444P 
    <i>GBA</i>-PD vs 6 non- 
    <i>GBA</i> PD (Germany) 
   </td>
   <td>4 + 8 years</td>
   <td>Postoperatively good response on UPDRS III-IV and LEDD reduction in both groups. On long-term follow-up more pronounced therapy-resistant axial symptoms and cognitive decline in 
    <i>GBA</i> group. 
   </td>
  </tr>
  <tr>
   <td>Lesage et al. 
    <sup>
     <a ref-type="bibr" rid="CR67">67</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>1 L422Pfs 
    <i>GBA</i>-PD + 1 homozygous N370S 
    <i>GBA</i>-PD (France) 
   </td>
   <td>2 years</td>
   <td>Both patients improved in motor function, with less fluctuations and dyskinesias after surgery, but one patient deteriorated due to postural instability.</td>
  </tr>
  <tr>
   <td>Chetrit et al. 
    <sup>
     <a ref-type="bibr" rid="CR68">68</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>1 N370S/V394L 
    <i>GBA</i>-PD +1 homozygous N370S 
    <i>GBA</i>-PD (Israel) 
   </td>
   <td>Unspecified</td>
   <td>Sustained symptomatic improvement.</td>
  </tr>
  <tr>
   <td>Dufournet et al. 
    <sup>
     <a ref-type="bibr" rid="CR18">18</a>
    </sup>
   </td>
   <td>Descriptive case series</td>
   <td>3 microdeletion 22q11.2-PD (France)</td>
   <td>Unspecified</td>
   <td>30%–70% improvement of the UPDRS-III score.</td>
  </tr>
  <tr>
   <td>Weiss et al. 
    <sup>
     <a ref-type="bibr" rid="CR71">71</a>
    </sup>
   </td>
   <td>Genetic association study of common SNPs versus DBS response</td>
   <td>85 DBS-treated PD genotyped for rs356219 or rs356220 ( 
    <i>SNCA</i>), 71 genotyped for rs1491923 ( 
    <i>LRRK2</i>) (Germany) 
   </td>
   <td>2 years</td>
   <td>rs356220 significantly associated with DBS response assessed by total UPDRS III as well as for the axial motor outcome. Common risk variant in the 
    <i>LRRK2</i> locus not associated. 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>AAO</i> age at onset of PD, 
   <i>AMSS</i> Age-Corrected Mayo’s Older Americans Normative Studies (MOANS) Scaled Score, 
   <i>BDI</i> Beck Depression Inventory, 
   <i>BDS</i> Brown’s Disability Scale, 
   <i>DBS</i> deep brain stimulation, 
   <i>EOPD</i> early-onset parkinson’s disease, 
   <i>GPi</i> Globus Pallidus internus, 
   <i>H &amp; Y</i> Hoehn and Yahr stage, 
   <i>iPD</i> idiopathic parkinson’s disease, 
   <i>LBP</i> lower back pain, 
   <i>LEDD</i> Levodopa equivalent daily dose, 
   <i>MC</i> mutation carrier, 
   <i>MMSE</i> Mini mental state examination, 
   <i>MDRS</i> Mattis Dementia Rating Scale, 
   <i>NC</i> non carrier, 
   <i>NMSS</i> non-motor symptom assessment scale, 
   <i>iPD</i> idiopathic Parkinson’s disease, 
   <i>PD</i> Parkinson’s disease, 
   <i>PDQ-39</i> Parkinson’s Disease Questionnaire, 
   <i>PIGD</i> postural instability and gait disorder, 
   <i>S&amp;E</i> Schwab and England quality of life scale, 
   <i>SNP</i> single-nucleotide polymorphism, 
   <i>STN</i> sucthalamic nucleus, 
   <i>UPDRS</i> Unified Parkinson’s disease rating scale 
  </p>
 </tfoot>
</table>
